Entera Bio LTD 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ENTX
Entera Bio LTDEntera Bio Ltd. reported increased net losses and declining revenue in 2025, raising substantial doubt about its ability to continue as a going concern without significant additional funding.
NASDAQ
ENTX
Entera Bio LTD10-K: Entera Bio Ltd. Reports Fiscal Year 2024 Results, Outlines Strategy for Oral Peptide Development
Entera Bio Ltd. files its 10-K report for the fiscal year ended December 31, 2024, highlighting its focus on developing oral peptide therapies and its plans for advancing key programs.
NASDAQ
ENTX
Entera Bio LTDEntera Bio Ltd. released its annual 10-K filing, detailing advancements in its oral peptide programs for osteoporosis and hypoparathyroidism, and a new collaboration with OPKO Biologics.